| ACE-I | Angiotensin-Converting Enzyme Inhibitor |
| advSM | Advanced Systemic Mastocytosis |
| AE | Adverse Event |
| AKT | Protein Kinase B |
| ARB | Angiotensin Receptor Blocker |
| ALK | Anaplastic Lymphoma Kinase |
| AXL | AXL Receptor Tyrosine Kinase |
| BCR-ABL | Fusion Oncoprotein Driving Chronic Myeloid Leukemia (CML) |
| BP | Blood Pressure |
| B-RAF | Serine/Threonine-Protein Kinase B-RAF |
| CBC | Complete Blood Count |
| C-KIT | Mast/Stem Cell Growth Factor Receptor |
| CML | Chronic Myeloid Leukemia |
| CSF-1R | Colony-Stimulating Factor 1 Receptor |
| CT | Computed Tomography |
| DVT | Deep Venous Thrombosis |
| EAP | Expanded Access Program |
| EGFR | Epidermal Growth Factor Receptor |
| ERK | Extracellular Signal-Regulated Kinase |
| FDA | U.S. Food and Drug Administration |
| FGFR | Fibroblast Growth Factor Receptor |
| FLT3 | FMS-Like Tyrosine Kinase 3 |
| G-CSF | Granulocyte Colony-Stimulating Factor |
| GI | Gastrointestinal |
| GIST | Gastrointestinal Stromal Tumor |
| HCC | Hepatocellular Carcinoma |
| HER | Human Epidermal Growth Factor Receptor |
| HF | Heart Failure |
| HFSR | Hand–Foot Skin Reaction |
| IFN-α | Interferon-Alpha |
| KIT | KIT Receptor Tyrosine Kinase |
| LFT/LFTs | Liver Function Test / Liver Function Tests |
| LVEF | Left Ventricular Ejection Fraction |
| MEK | Mitogen-Activated Protein Kinase |
| MET | MET (HGF) Receptor Tyrosine Kinase |
| mCRC | Metastatic Colorectal Cancer |
| MRI | Magnetic Resonance Imaging |
| mRCC | Metastatic Renal Cell Carcinoma |
| NET | Neuroendocrine Tumor |
| ORR | Objective Response Rate / Overall Response Rate |
| OS | Overall Survival |
| PDGFRα(A)/β(B) | Platelet-Derived Growth Factor Receptors Alpha and Beta |
| PFS | Progression-Free Survival |
| PI3K | Phosphoinositide 3-Kinase |
| PK/PD | Pharmacokinetics/Pharmacodynamics |
| pNET/pNETs | Pancreatic Neuroendocrine Tumor(s) |
| RAS | Rat Sarcoma Protein |
| RAF | Rapidly Accelerated Fibrosarcoma Kinase |
| RCC | Renal Cell Carcinoma |
| RET | RET Receptor Tyrosine Kinase |
| R0 | Complete Resection with Negative Margins |
| RFS | Recurrence-Free Survival |
| ROS1 | Proto-Oncogene Tyrosine-Protein Kinase ROS |
| SDH | Succinate Dehydrogenase |
| TEAE | Treatment-Emergent Adverse Event |
| TIE2 | Angiogenesis Receptor Tyrosine Kinase |
| TKI/TKIs | Tyrosine Kinase Inhibitor(s) |
| TIE2 | Tunica Interna Endothelial Cell Kinase 2 |
| TRKs | Tropomyosin Receptor Tyrosine Kinases |
| TSH | Thyroid-Stimulating Hormone |
| TTP | Time to Progression |
| VEGF | Vascular Endothelial Growth Factor |
| VEGFR1–3 | Vascular Endothelial Growth Factor Receptors 1–3 |